论文部分内容阅读
采用蛋白酪氨酸磷酸酯酶(PTP1B)、二肽基肽酶(DPP-IV)、α-葡萄糖苷酶-rat(α-glucosidase-rat)、MCF-7/ADR肿瘤耐药细胞增敏、肿瘤细胞毒活性(HepG2肝癌细胞)、骨髓有核细胞增殖等模型,对雪灵芝水提物、醇提物和市售的雪灵芝营养口服液分别进行体外免疫调节、抗肿瘤、糖尿病等活性筛选.结果表明:雪灵芝水提物、醇提物和营养口服液均对蛋白酪氨酸磷酸酯酶/PTP1B模型呈阳性,对其余5种模型呈阴性,说明蛋白酪氨酸磷酸酯酶(PTP1B)模型可以作为雪灵芝有效部位的活性跟踪模型.
The use of protein tyrosine phosphatase (PTP1B), dipeptidyl peptidase (DPP-IV), α-glucosidase-rat, MCF-7/ADR tumor cell sensitization, Models of tumor cytotoxicity (HepG2 hepatocellular carcinoma cells), bone marrow nucleated cell proliferation, etc., In vitro immunomodulatory, anti-tumor, and diabetes screening of snow ganoderma lucidum aqueous extracts, alcohol extracts, and commercial ganoderma lucidum nutritional oral liquids The results showed that the water ganoderma lucidum extracts, alcohol extracts and oral liquids were positive for the protein tyrosine phosphatase/PTP1B model and negative for the other five models, indicating that the protein tyrosine phosphatase (PTP1B The model can be used as an activity tracking model for active ganoderma lucidum.